^
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
venetoclax Sensitive: A1 - Approval
|
venetoclax Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
ibrutinib Sensitive: A1 - Approval
|
ibrutinib Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
rituximab + idelalisib Sensitive: A1 - Approval
|
rituximab + idelalisib Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
acalabrutinib Sensitive: A1 - Approval
|
acalabrutinib Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
idelalisib + ofatumumab Sensitive: A1 - Approval
|
idelalisib + ofatumumab Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
ofatumumab Sensitive: A2 - Guideline
|
ofatumumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
zanubrutinib Sensitive: A2 - Guideline
|
zanubrutinib Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
zanubrutinib Sensitive: A2 - Guideline
|
zanubrutinib Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
ibrutinib Sensitive: A2 - Guideline
|
ibrutinib Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
idelalisib Sensitive: A2 - Guideline
|
idelalisib Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
ofatumumab Sensitive: A2 - Guideline
|
ofatumumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
idelalisib Sensitive: A2 - Guideline
|
idelalisib Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
venetoclax Sensitive: A2 - Guideline
|
venetoclax Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
rituximab + idelalisib Sensitive: A2 - Guideline
|
rituximab + idelalisib Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
duvelisib Sensitive: A2 - Guideline
|
duvelisib Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
obinutuzumab Sensitive: A2 - Guideline
|
obinutuzumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
alemtuzumab Sensitive: A2 - Guideline
|
alemtuzumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
venetoclax + obinutuzumab Sensitive: A2 - Guideline
|
venetoclax + obinutuzumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
acalabrutinib Sensitive: A2 - Guideline
|
acalabrutinib Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
lenalidomide Sensitive: A2 - Guideline
|
lenalidomide Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
lenalidomide Sensitive: A2 - Guideline
|
lenalidomide Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
alemtuzumab Sensitive: A2 - Guideline
|
alemtuzumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
duvelisib Sensitive: A2 - Guideline
|
duvelisib Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
obinutuzumab Sensitive: A2 - Guideline
|
obinutuzumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
pembrolizumab + ibrutinib Sensitive: A2 - Guideline
|
pembrolizumab + ibrutinib Sensitive: A2 - Guideline
|
Chr del(17p)
|
Multiple Myeloma
|
Chr del(17p)
|
Multiple Myeloma
|
bortezomib + selinexor Sensitive: B - Late Trials
|
bortezomib + selinexor Sensitive: B - Late Trials
|
Chr del(17p)
|
Multiple Myeloma
|
Chr del(17p)
|
Multiple Myeloma
|
DVD Sensitive: B - Late Trials
|
DVD Sensitive: B - Late Trials
|
Chr del(17p)
|
Multiple Myeloma
|
Chr del(17p)
|
Multiple Myeloma
|
lenalidomide + elotuzumab Sensitive: B - Late Trials
|
lenalidomide + elotuzumab Sensitive: B - Late Trials
|
Chr del(17p)
|
Multiple Myeloma
|
Chr del(17p)
|
Multiple Myeloma
|
daratumumab Sensitive: B - Late Trials
|
daratumumab Sensitive: B - Late Trials
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
ibrutinib + ublituximab Sensitive: B - Late Trials
|
ibrutinib + ublituximab Sensitive: B - Late Trials
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
obinutuzumab Resistant: B - Late Trials
|
obinutuzumab Resistant: B - Late Trials
|
Chr del(17p)
|
Multiple Myeloma
|
Chr del(17p)
|
Multiple Myeloma
|
Isa-KRd Sensitive: C2 – Inclusion Criteria
|
Isa-KRd Sensitive: C2 – Inclusion Criteria
|
Chr del(17p)
|
NHL
|
Chr del(17p)
|
NHL
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
lenalidomide + tafasitamab Sensitive: C3 – Early Trials
|
lenalidomide + tafasitamab Sensitive: C3 – Early Trials
|
Chr del(17p)
|
Multiple Myeloma
|
Chr del(17p)
|
Multiple Myeloma
|
lenalidomide + ixazomib Sensitive: C3 – Early Trials
|
lenalidomide + ixazomib Sensitive: C3 – Early Trials
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
LOXO-305 Sensitive: C3 – Early Trials
|
LOXO-305 Sensitive: C3 – Early Trials
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
LOXO-305 Sensitive: C3 – Early Trials
|
LOXO-305 Sensitive: C3 – Early Trials
|
Chr del(17p)
|
Multiple Myeloma
|
Chr del(17p)
|
Multiple Myeloma
|
Proteasome inhibitor + Immunomodulator Resistant: C3 – Early Trials
|
Proteasome inhibitor + Immunomodulator Resistant: C3 – Early Trials
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
RP6530 Sensitive: C3 – Early Trials
|
RP6530 Sensitive: C3 – Early Trials
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
ICP-022 Sensitive: C3 – Early Trials
|
ICP-022 Sensitive: C3 – Early Trials
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
ICP-022 Sensitive: C3 – Early Trials
|
ICP-022 Sensitive: C3 – Early Trials
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
venetoclax + ibrutinib Sensitive: C3 – Early Trials
|
venetoclax + ibrutinib Sensitive: C3 – Early Trials
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
obinutuzumab + zanubrutinib Sensitive: C3 – Early Trials
|
obinutuzumab + zanubrutinib Sensitive: C3 – Early Trials
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
obinutuzumab + zanubrutinib Sensitive: C3 – Early Trials
|
obinutuzumab + zanubrutinib Sensitive: C3 – Early Trials
|
Chr del(17p)
|
AML
|
Chr del(17p)
|
AML
|
MGD006 Sensitive: C3 – Early Trials
|
MGD006 Sensitive: C3 – Early Trials
|
Chr del(17p)
|
Multiple Myeloma
|
Chr del(17p)
|
Multiple Myeloma
|
melphalan flufenamide Sensitive: C3 – Early Trials
|
melphalan flufenamide Sensitive: C3 – Early Trials
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
FCR Sensitive: C3 – Early Trials
|
FCR Sensitive: C3 – Early Trials
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
FCR Sensitive: C3 – Early Trials
|
FCR Sensitive: C3 – Early Trials
|
Chr del(17p)
|
MDS
|
Chr del(17p)
|
MDS
|
azacitidine Resistant: C3 – Early Trials
|
azacitidine Resistant: C3 – Early Trials
|
Chr del(17p)
|
Multiple Myeloma
|
Chr del(17p)
|
Multiple Myeloma
|
thalidomide Resistant: C3 – Early Trials
|
thalidomide Resistant: C3 – Early Trials
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
ibrutinib + UC-961 Sensitive: C3 – Early Trials
|
ibrutinib + UC-961 Sensitive: C3 – Early Trials
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
venetoclax + ibrutinib Sensitive: C3 – Early Trials
|
venetoclax + ibrutinib Sensitive: C3 – Early Trials
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
ibrutinib + lisocabtagene maraleucel Sensitive: C3 – Early Trials
|
ibrutinib + lisocabtagene maraleucel Sensitive: C3 – Early Trials
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
ibrutinib + lisocabtagene maraleucel Sensitive: C3 – Early Trials
|
ibrutinib + lisocabtagene maraleucel Sensitive: C3 – Early Trials
|
Chr del(17p)
|
Multiple Myeloma
|
Chr del(17p)
|
Multiple Myeloma
|
bortezomib Sensitive: D – Preclinical
|
bortezomib Sensitive: D – Preclinical
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
Compound C Sensitive: D – Preclinical
|
Compound C Sensitive: D – Preclinical
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
hydroxychloroquine Sensitive: D – Preclinical
|
hydroxychloroquine Sensitive: D – Preclinical
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
MRT68921 Sensitive: D – Preclinical
|
MRT68921 Sensitive: D – Preclinical
|
